GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » 3-Year FCF Growth Rate

Jenscare Scientific Co (HKSE:09877) 3-Year FCF Growth Rate : -17.80% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co 3-Year FCF Growth Rate?

Jenscare Scientific Co's Free Cash Flow per Share for the six months ended in Dec. 2024 was HK$-0.42.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Jenscare Scientific Co was -17.80% per year. The lowest was -78.00% per year. And the median was -47.90% per year.


Competitive Comparison of Jenscare Scientific Co's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Jenscare Scientific Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenscare Scientific Co's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Jenscare Scientific Co's 3-Year FCF Growth Rate falls into.


;
;

Jenscare Scientific Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Jenscare Scientific Co  (HKSE:09877) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Jenscare Scientific Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Li Hui 2501 Other
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Lv Shiwen 2501 Other
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Pan Fei 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner
Ningbo Mukang Venture Capital Partnership (limited Partnership)

Jenscare Scientific Co Headlines

No Headlines